玛伐凯泰治疗梗阻性肥厚型心肌病左心房功能的时间变化:VALOR-HCM试验启示
VALOR-HCM试验纳入112例有症状梗阻性肥厚型心肌病患者,评估玛伐凯泰对左心房应变的影响。56周时左心房容积指数和左心房应变(导管、收缩、储备)均显著改善,但房颤亚组无显著改善。
要点
- 玛伐凯泰治疗56周使左心房容积指数和左心房应变显著改善,提示左心房逆重构。
- 有房颤病史患者左心房应变各指标从基线至56周无显著改善。
- 玛伐凯泰对左心房重构的有利影响能否降低肥厚型心肌病高房性快速心律失常负荷尚待证实。
核心结论
- 在VALOR-HCM试验中,玛伐凯泰治疗至第56周使左心房容积指数和左心房应变改善,提示持续有利的左心房重构和功能改善,但房颤亚组除外。
研究设计与样本
- VALOR-HCM试验纳入112例有症状梗阻性肥厚型心肌病患者(平均年龄60岁,51%男性),基线接受玛伐凯泰者(n=56)继续治疗56周,安慰剂组(n=52)从第16周转为玛伐凯泰至第56周。
关键影像表现/征象
- 基线时左心房容积指数为41.3 ± 16.5 mL/m2,导管应变、收缩应变、储备应变分别为-11.8% ± 6.5%、-8.7% ± 5.0%、20.5% ± 8.7%,均差于报道的正常值。
- 从基线至第56周左心房容积指数显著改善-5.6 ± 9.7 mL/m2(P < 0.001)。
- 从基线至第56周左心房应变绝对值显著改善(P < 0.05):导管应变-1.7% ± 6%,收缩应变-1.2% ± 4.5%,储备应变2.8% ± 7.7%。
- 最初接受安慰剂的患者至第16周左心房测量无差异。
- 有房颤病史患者从基线至第56周左心房应变无显著改善:导管应变-0.9% ± 3.8%,收缩应变-0.4% ± 3.4%,储备应变1.4% ± 6.1%(P = 不显著)。
局限性
- 玛伐凯泰长期治疗相关的有利左心房重构能否对肥厚型心肌病中观察到的高房性快速心律失常负荷产生有利影响尚待证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: In severely symptomatic patients with obstructive hypertrophic cardiomyopathy (HCM), the VALOR-HCM (A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Who Are Eligible for Septal Reduction Therapy) trial showed that mavacamten reduced the eligibility for septal reduction therapy with sustained improvement in left ventricular outflow tract gradients. Mavacamten also resulted in favorable cardiac remodeling, including improvement in biomarkers (eg, N-terminal pro-B-type natriuretic peptide and troponin T). However, the impact of mavacamten on left atrial (LA) function is unknown.
OBJECTIVES: The aim of this study was to assess serial changes in LA strain measures in patients enrolled in the VALOR-HCM trial.
METHODS: VALOR-HCM included 112 symptomatic patients with obstructive HCM (mean age 60 years; 51% male). Patients assigned to receive mavacamten at baseline (n = 56) continued therapy for 56 weeks and those assigned to placebo transitioned to mavacamten (n = 52) from week 16 to week 56. Echocardiographic LA strain (reservoir, conduit, and contraction) was measured by using a vendor-neutral postprocessing software.
RESULTS: At baseline, the mean LA volume index (LAVI) and LA strain values (conduit, contraction, and reservoir) were 41.3 ± 16.5 mL/m2, -11.8% ± 6.5%, -8.7% ± 5.0%, and 20.5% ± 8.7%, respectively (all worse than reported normal). LAVI significantly improved by -5.6 ± 9.7 mL/m2 from baseline to week 56 (P < 0.001). There was a significant (P < 0.05) improvement in absolute LA strain values from baseline to week 56 (conduit [-1.7% ± 6%], contraction [-1.2% ± 4.5%], and reservoir [2.8% ± 7.7%]). Patients originally receiving placebo had no differences in LA measurements up to week 16. There was no significant improvement in LA strain values (conduit [-0.9% ± 3.8%], contraction [-0.4% ± 3.4%], and reservoir [1.4% ± 6.1%]; all; P = not significant) from baseline to week 56 in patients with history of atrial fibrillation.
CONCLUSIONS: In VALOR-HCM, mavacamten resulted in an improvement in LAVI and LA strain at week 56, suggesting sustained favorable LA remodeling and improved function, except in the atrial fibrillation subgroup. Whether the advantageous LA remodeling associated with long-term treatment with mavacamten results in a favorable impact on the observed high burden of atrial tachyarrhythmias in HCM remains to be proven. (A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Who Are Eligible for Septal Reduction Therapy [VALOR-HCM]; NCT04349072).
引用
- Desai MY, Okushi Y, Wolski K, et al. Mavacamten-Associated Temporal Changes in Left Atrial Function in Obstructive HCM: Insights From the VALOR-HCM Trial. JACC Cardiovasc Imaging. 2024. PMID: 39254622. doi:10.1016/j.jcmg.2024.08.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。